Breyanzi
Breyanzi is a medicine authorised by Swissmedic under authorisation number 67469. The authorisation holder is Bristol-Myers Squibb SA. The medicinal product code is Transplant: gene therapy product and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 28 March 2022 and the authorisation is valid without a time limit. ATC code L01XL08 places the medicine in the group Antineoplastic agents.
| Authorisation number | 67469 |
|---|---|
| Name | Breyanzi |
| Full name | Breyanzi, Suspension |
| Authorisation holder | Bristol-Myers Squibb SA |
| Medicinal product code | Transplant: gene therapy product |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01XL08 |
| First authorisation | 28 March 2022 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Breyanzi, Suspension | A | 28 March 2022 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 bis 4 | Durchstechflasche(n) | L01XL08 | 07.16.4. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Breyanzi authorised in Switzerland?
Yes. Breyanzi is authorised by Swissmedic under authorisation number 67469, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Breyanzi have?
Breyanzi is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Breyanzi?
The authorisation holder is Bristol-Myers Squibb SA. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.